MENU
+Compare
CTNM
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$4.11
Change
+$0.10 (+2.49%)
Capitalization
106.33M

CTNM Contineum Therapeutics Forecast, Technical & Fundamental Analysis

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need... Show more

CTNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CTNM with price predictions
Jun 27, 2025

CTNM sees its Stochastic Oscillator recovers from oversold territory

On June 23, 2025, the Stochastic Oscillator for CTNM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 9 instances where the indicator left the oversold zone. In of the 9 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for CTNM crossed bullishly above the 50-day moving average on June 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CTNM as a result. In of 19 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CTNM turned negative on June 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at .

CTNM moved below its 50-day moving average on June 26, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CTNM broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CTNM entered a downward trend on June 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.575) is normal, around the industry mean (16.366). P/E Ratio (26.395) is within average values for comparable stocks, (58.189). CTNM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (10.101) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CTNM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CTNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CTNM is expected to report earnings to fall 54.84% to -28 cents per share on August 19

Contineum Therapeutics CTNM Stock Earnings Reports
Q2'25
Est.
$-0.28
Q1'25
Missed
by $0.20
Q4'24
Missed
by $0.11
Q3'24
Missed
by $0.04
Q2'24
Missed
by $0.03
The last earnings report on May 15 showed earnings per share of -62 cents, missing the estimate of -41 cents. With 1.31M shares outstanding, the current market capitalization sits at 106.33M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10578 Science Center Drive
Phone
+1 858 333-5280
Employees
31
Web
https://www.contineum-tx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JBAXY13.400.16
+1.21%
Julius Baer Group Ltd.
SPHRF0.07N/A
N/A
Starpharma Holdings Ltd.
BMYMP801.01N/A
N/A
Bristol-Myers Squibb Co.
MDALF25.05-0.09
-0.36%
MDA Space Ltd.
CLVLY6.80-0.18
-2.58%
Clinuvel Pharmaceuticals Ltd.

CTNM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CTNM has been loosely correlated with CCCC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CTNM jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTNM
1D Price
Change %
CTNM100%
+2.74%
CCCC - CTNM
36%
Loosely correlated
-7.89%
XNCR - CTNM
31%
Poorly correlated
-3.10%
VYGR - CTNM
31%
Poorly correlated
-0.34%
GBIO - CTNM
31%
Poorly correlated
-15.40%
ARMP - CTNM
30%
Poorly correlated
+4.71%
More